PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.75

Change

-0.08 (-2.83)%

Market Cap

N/A

Volume

0.62M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+0.84 (+0.19%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

+0.94 (+0.14%)

USD 78.92B
ARGX argenx NV ADR

+6.65 (+1.03%)

USD 39.62B
ALNY Alnylam Pharmaceuticals Inc

-5.20 (-1.86%)

USD 30.22B
MRNA Moderna Inc

-4.22 (-9.39%)

USD 18.29B
RPRX Royalty Pharma Plc

+0.01 (+0.03%)

USD 18.12B
SMMT Summit Therapeutics PLC

-1.86 (-7.91%)

USD 17.52B
UTHR United Therapeutics Corporatio..

+1.90 (+0.51%)

USD 15.91B
INCY Incyte Corporation

+0.57 (+0.78%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+0.21 (+0.33%)

USD 12.74B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.82% 47% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.82% 47% F 26% F
Trailing 12 Months  
Capital Gain -56.69% 30% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.69% 30% F 14% F
Trailing 5 Years  
Capital Gain -86.41% 39% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -86.41% 39% F 12% F
Average Annual (5 Year Horizon)  
Capital Gain -24.48% 17% F 9% A-
Dividend Return -24.48% 17% F 9% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.20% 92% A 68% D+
Risk Adjusted Return -93.45% 8% B- 4% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector